AVALIAÇÃO INSTITUCIONAL PARTICIPATIVA: O OLHAR A PARTIR DA REALIDADE DE UMA ESCOLA ESTADUAL EM SÃO PAULO – BRASIL

Este trabalho tem como objetivo discutir a avaliação institucional participativa no ensino fundamental, evidenciando os limites e as potencialidades de sua efetivação na prática, com ênfase na participação. Compreendemos a necessidade de democratização das escolas e buscamos destacar o processo de avaliação institucional participativa como um dos instrumentos para concretizá-la; no entanto, reconhecemos que há limites dentro da realidade escolar. Trata-se de uma pesquisa qualitativa, realizada a partir de observações em uma escola estadual paulista, denominada Gama, e da análise dos documentos encaminhados à escola sobre avaliação institucional. A qualidade educacional requer uma compreensão de avaliação formativa que, no cotidiano escolar, deve envolver a participação da comunidade.Palavras-chave: Avaliação institucional participativa. Ensino fundamental. Quali­dade educacional

MPAS-Albany Land Ice (MALI): a variable-resolution ice sheet model for Earth system modeling using Voronoi grids

We introduce MPAS-Albany Land Ice (MALI) v6.0, a new variable-resolution land ice model that uses unstructured Voronoi grids on a plane or sphere. MALI is built using the Model for Prediction Across Scales (MPAS) framework for developing variable-resolution Earth system model components and the Albany multi-physics code base for the solution of coupled systems of partial differential equations, which itself makes use of Trilinos solver libraries. MALI includes a three-dimensional first-order momentum balance solver (Blatter–Pattyn) by linking to the Albany-LI ice sheet velocity solver and an explicit shallow ice velocity solver. The evolution of ice geometry and tracers is handled through an explicit first-order horizontal advection scheme with vertical remapping. The evolution of ice temperature is treated using operator splitting of vertical diffusion and horizontal advection and can be configured to use either a temperature or enthalpy formulation. MALI includes a mass-conserving subglacial hydrology model that supports distributed and/or channelized drainage and can optionally be coupled to ice dynamics. Options for calving include eigencalving, which assumes that the calving rate is proportional to extensional strain rates. MALI is evaluated against commonly used exact solutions and community benchmark experiments and shows the expected accuracy. Results for the MISMIP3d benchmark experiments with MALI's Blatter–Pattyn solver fall between published results from Stokes and L1L2 models as expected. We use the model to simulate a semi-realistic Antarctic ice sheet problem following the initMIP protocol and using 2&thinsp;km resolution in marine ice sheet regions. MALI is the glacier component of the Energy Exascale Earth System Model (E3SM) version 1, and we describe current and planned coupling to other E3SM components.</p

Polymorphous adenocarcinoma of the salivary glands : reappraisal and update

Although relatively rare, polymorphous adenocarcinoma (PAC) is likely the second most common malignancy of the minor salivary glands (MiSG). The diagnosis is mainly based on an incisional biopsy. The optimal treatment comprises wide surgical excision, often with adjuvant radiotherapy. In general, PAC has a good prognosis. Previously, PAC was referred to as polymorphous low-grade adenocarcinoma (PLGA), but the new WHO classification of salivary gland tumours has also included under the PAC subheading, the so-called cribriform adenocarcinoma of minor salivary glands (CAMSG). This approach raised controversy, predominantly because of possible differences in clinical behaviour. For example, PLGA (PAC, classical variant) only rarely metastasizes, whereas CAMSG often shows metastases to the neck lymph nodes. Given the controversy, this review reappraises the definition, epidemiology, clinical presentation, diagnostic work-up, genetics, treatment modalities, and prognosis of PAC of the salivary glands with a particular focus on contrasting differences with CAMSG.Peer reviewe

Controversies in the management of advanced prostate cancer

For advanced prostate cancer, the main hormone treatment against which other treatments are assessed is surgical castration. It is simple, safe and effective, however it is not acceptable to all patients. Medical castration by means of luteinizing hormone-releasing hormone (LH-RH) analogues such as goserelin acetate provides an alternative to surgical castration. Diethylstilboestrol, previously the only non-surgical alternative to orchidectomy, is no longer routinely used. Castration reduces serum testosterone by around 90%, but does not affect androgen biosynthesis in the adrenal glands. Addition of an anti-androgen to medical or surgical castration blocks the effect of remaining testosterone on prostate cells and is termed combined androgen blockade (CAB). CAB has now been compared with castration alone (medical and surgical) in numerous clinical trials. Some trials show advantage of CAB over castration, whereas others report no significant difference. The author favours the view that CAB has an advantage over castration. No study has reported that CAB is less effective than castration. Of the anti-androgens which are available for use in CAB, bicalutamide may be associated with a lower incidence of side-effects compared with the other non-steroidal anti-androgens and, in common with nilutamide, has the advantage of once-daily dosing. Only one study has compared anti-androgens within CAB: bicalutamide plus LH-RH analogue and flutamide plus LH-RH analogue. At 160-week follow-up, the groups were equivalent in terms of survival and time to progression. However, bicalutamide caused significantly less diarrhoea than flutamide. Withdrawal and intermittent therapy with anti-androgens extend the range of treatment options. © 1999 Cancer Research Campaig

Evidence-Based PET for Abdominal and Pelvic Tumours

Evidence-based data about the usefulness of positron emission tomography (PET) and hybrid imaging methods (PET/CT and PET/MRI) in abdominal and pelvic tumours have been collected and discussed in this chapter. These data were divided in three sections: (1) gastrointestinal tumours, (2) uro-genital tumours, (3) gynaecological tumours. Several pooled data (diagnostic and prognostic data), clinical settings (e.g. staging, restaging, treatment evaluation) and radiotracers as fluorine-18 fluorodeoxyglucose (18F-FDG), radiolabelled choline and prostate-specific membrane antigen (PSMA) were considered